Julie M. Vose, MD, MBA Of the FDA-approved bispecific antibodies for patients with relapsed/refractory large B-cell lymphoma (LBCL), including diffuse LBCL (DLBCL) and follicular lymphoma, epcoritamab (Epkinly) produced the longest reported median duration of complete response (DOCR) to date, according to 3-year follow-up results from the phase 1/2 EPCORE NHL-1 trial (NCT03625037). 1 “The patients who maintained [treatment with epcoritamab] continued to increase their MRD-negativity over time,” Julie M.
Vose, MD, MBA, stated during an interview with OncLive ® about the trial. “The bottom line is that [epcoritamab] doesn't benefit all patients. However, for those patients who do experience a good response to [epcoritamab], it can be very durable, and a high percentage of patients can become MRD-negative.
” The overall median DOCR with epcoritamab was 36.1 months (95% CI, 20.2–not reached).
In patients with LBCL (n = 157), the overall response rate (ORR) was 59%, with a CR rate of 41% and a partial response rate of 17%; in those with DLBCL transformed from follicular lymphoma (n = 32), these rates were 50%, 44%, and 6%. The median duration of response was 20.8% (95% CI, 13.
0-32.0) in patients with LBCL and NR (95% CI, 10.6–NR) in patients with DLBCL transformed from follicular lymphoma; the respective 36-month estimates were 39% and 55%.
In the interview, Vose discussed long-term findings from the EPCORE NHL-1 trial, the safety profile of epcoritamab, and the optima.
